Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

1.

Porphyromonas gingivalis-derived lysine gingipain enhances osteoclast differentiation induced by tumor necrosis factor-α and interleukin-1β but suppresses that by interleukin-17A: importance of proteolytic degradation of osteoprotegerin by lysine gingipain.

Akiyama T, Miyamoto Y, Yoshimura K, Yamada A, Takami M, Suzawa T, Hoshino M, Imamura T, Akiyama C, Yasuhara R, Mishima K, Maruyama T, Kohda C, Tanaka K, Potempa J, Yasuda H, Baba K, Kamijo R.

J Biol Chem. 2014 May 30;289(22):15621-30. doi: 10.1074/jbc.M113.520510. Epub 2014 Apr 22.

PMID:
24755218
[PubMed - in process]
2.

Lysine-specific gingipain promotes lipopolysaccharide- and active-vitamin D3-induced osteoclast differentiation by degrading osteoprotegerin.

Yasuhara R, Miyamoto Y, Takami M, Imamura T, Potempa J, Yoshimura K, Kamijo R.

Biochem J. 2009 Apr 1;419(1):159-66. doi: 10.1042/BJ20081469.

PMID:
19102726
[PubMed - indexed for MEDLINE]
Free Article
4.

Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway.

Palmqvist P, Lundberg P, Persson E, Johansson A, Lundgren I, Lie A, Conaway HH, Lerner UH.

J Biol Chem. 2006 Feb 3;281(5):2414-29. Epub 2005 Oct 25.

PMID:
16251181
[PubMed - indexed for MEDLINE]
Free Article
5.

A novel molecular mechanism modulating osteoclast differentiation and function.

Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Goto M, Mochizuki SI, Tsuda E, Morinaga T, Udagawa N, Takahashi N, Suda T, Higashio K.

Bone. 1999 Jul;25(1):109-13.

PMID:
10423033
[PubMed - indexed for MEDLINE]
6.

Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation.

Suda K, Udagawa N, Sato N, Takami M, Itoh K, Woo JT, Takahashi N, Nagai K.

J Immunol. 2004 Feb 15;172(4):2504-10.

PMID:
14764723
[PubMed - indexed for MEDLINE]
Free Article
8.

Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells.

Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S.

Bone. 1999 Sep;25(3):255-9.

PMID:
10495128
[PubMed - indexed for MEDLINE]
9.

Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene.

Enomoto H, Shiojiri S, Hoshi K, Furuichi T, Fukuyama R, Yoshida CA, Kanatani N, Nakamura R, Mizuno A, Zanma A, Yano K, Yasuda H, Higashio K, Takada K, Komori T.

J Biol Chem. 2003 Jun 27;278(26):23971-7. Epub 2003 Apr 15.

PMID:
12697767
[PubMed - indexed for MEDLINE]
Free Article
10.

Inhibitory effects of orally administrated liposomal bovine lactoferrin on the LPS-induced osteoclastogenesis.

Yamano E, Miyauchi M, Furusyo H, Kawazoe A, Ishikado A, Makino T, Tanne K, Tanaka E, Takata T.

Lab Invest. 2010 Aug;90(8):1236-46. doi: 10.1038/labinvest.2010.80. Epub 2010 Apr 26.

PMID:
20421871
[PubMed - indexed for MEDLINE]
Free Article
12.

Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts.

Chung YH, Chang EJ, Kim SJ, Kim HH, Kim HM, Lee SB, Ko JS.

J Periodontal Res. 2006 Aug;41(4):288-96.

PMID:
16827722
[PubMed - indexed for MEDLINE]
13.

The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells.

Kwan Tat S, Pelletier JP, Lajeunesse D, Fahmi H, Lavigne M, Martel-Pelletier J.

Clin Exp Rheumatol. 2008 Mar-Apr;26(2):295-304.

PMID:
18565252
[PubMed - indexed for MEDLINE]
14.

Macrophage-elicited osteoclastogenesis in response to bacterial stimulation requires Toll-like receptor 2-dependent tumor necrosis factor-alpha production.

Ukai T, Yumoto H, Gibson FC 3rd, Genco CA.

Infect Immun. 2008 Feb;76(2):812-9. Epub 2007 Nov 12.

PMID:
17998311
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.

Cao JJ, Wronski TJ, Iwaniec U, Phleger L, Kurimoto P, Boudignon B, Halloran BP.

J Bone Miner Res. 2005 Sep;20(9):1659-68. Epub 2005 May 2.

PMID:
16059637
[PubMed - indexed for MEDLINE]
16.

Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.

Kon T, Cho TJ, Aizawa T, Yamazaki M, Nooh N, Graves D, Gerstenfeld LC, Einhorn TA.

J Bone Miner Res. 2001 Jun;16(6):1004-14.

PMID:
11393777
[PubMed - indexed for MEDLINE]
17.

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T.

Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3597-602.

PMID:
9520411
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Porphyromonas gingivalis regulates the RANKL-OPG system in bone marrow stromal cells.

Reddi D, Bostanci N, Hashim A, Aduse-Opoku J, Curtis MA, Hughes FJ, Belibasakis GN.

Microbes Infect. 2008 Nov-Dec;10(14-15):1459-68. doi: 10.1016/j.micinf.2008.08.007. Epub 2008 Aug 26.

PMID:
18789397
[PubMed - indexed for MEDLINE]
20.

RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.

Sordillo EM, Pearse RN.

Cancer. 2003 Feb 1;97(3 Suppl):802-12. Review.

PMID:
12548579
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk